Xtandi Kesatuan Eropah - Finland - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatiset kasvaimet - endokriinihoito - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Imbruvica Kesatuan Eropah - Finland - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Salmeson 50 mikrog / 250 mikrog / annos inhalaatiojauhe, annosteltu Finland - Finland - Fimea (Suomen lääkevirasto)

salmeson 50 mikrog / 250 mikrog / annos inhalaatiojauhe, annosteltu

elpen pharmaceutical co. inc. - salmeterol xinafoate, fluticasone propionate - inhalaatiojauhe, annosteltu - 50 mikrog / 250 mikrog / annos - salmeteroli ja flutikasoni

Salmeson 50 mikrog / 500 mikrog / annos inhalaatiojauhe, annosteltu Finland - Finland - Fimea (Suomen lääkevirasto)

salmeson 50 mikrog / 500 mikrog / annos inhalaatiojauhe, annosteltu

elpen pharmaceutical co. inc. - salmeterol xinafoate, fluticasone propionate - inhalaatiojauhe, annosteltu - 50 mikrog / 500 mikrog / annos - salmeteroli ja flutikasoni

DUTASTERIDE/TAMSULOSINHYDROCHLORIDE HEXAL 0.5 mg / 0.4 mg kapseli, kova Finland - Finland - Fimea (Suomen lääkevirasto)

dutasteride/tamsulosinhydrochloride hexal 0.5 mg / 0.4 mg kapseli, kova

hexal a/s - tamsulosini hydrochloridum,dutasteridum - kapseli, kova - 0.5 mg / 0.4 mg - tamsulosiini ja dutasteridi

Gasterix 15 mg enterokapseli, kova Finland - Finland - Fimea (Suomen lääkevirasto)

gasterix 15 mg enterokapseli, kova

ratiopharm gmbh - lansoprazole - enterokapseli, kova - 15 mg - lansopratsoli

Gasterix 30 mg enterokapseli, kova Finland - Finland - Fimea (Suomen lääkevirasto)

gasterix 30 mg enterokapseli, kova

ratiopharm gmbh - lansoprazole - enterokapseli, kova - 30 mg - lansopratsoli

Zolt 15 mg enterokapseli, kova Finland - Finland - Fimea (Suomen lääkevirasto)

zolt 15 mg enterokapseli, kova

orion corporation - lansoprazole - enterokapseli, kova - 15 mg - lansopratsoli

Zolt 30 mg enterokapseli, kova Finland - Finland - Fimea (Suomen lääkevirasto)

zolt 30 mg enterokapseli, kova

orion corporation - lansoprazole - enterokapseli, kova - 30 mg - lansopratsoli

Tamsucinfa 0.4 mg säädellysti vapauttava kapseli, kova Finland - Finland - Fimea (Suomen lääkevirasto)

tamsucinfa 0.4 mg säädellysti vapauttava kapseli, kova

synthon b.v. - tamsulosin hydrochloride - säädellysti vapauttava kapseli, kova - 0.4 mg - tamsulosiini